A 'transformative' gene therapy for haemophilia B
Costly treatment that could be 'truly life-changing' for patients with rare blood disorder gets funding boost
The NHS can now offer patients with a rare blood disorder a "transformative" new treatment after the UK's medicines watchdog gave its funding the green light.
Around 200 people with haemophilia B will be eligible for the gene therapy, which helps their body produce blood-clotting factors and "frees" them from regular treatments, said Bloomberg.
What is haemophilia B?
This genetic disorder is much rarer than haemophilia A, said Great Ormond Street Hospital (GOSH). Around 2,000 people in the UK have the condition.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Due to a mutation in their DNA, patients with haemophilia B either can't produce enough of factor IX – a specific protein that makes blood clot – or lack it entirely. "Without this crucial clotting component, bleeds are bigger and longer," said the BBC.
Treating haemophilia B requires constant care and monitoring. As a preventative course of treatment, people with the blood disorder receive weekly injections of factor IX to enable their blood to coagulate, said GOSH. On-demand injections are also administered if a patient injures themselves or undergoes surgery.
How does this gene therapy work?
The drug, Hemgenix, has been found to have long-term benefits for those with the condition. Clinical trials began in 2019, with 54 male patients from the US, EU and UK taking part. Then the gene therapy was "still just an experimental idea", said the BBC.
The therapy is administered as a "one-off infusion, lasting about an hour". Patients receive "engineered viruses" with "copies of the fully functional factor IX instructions". The viruses then "act like a fleet of microscopic postmen, delivering those blueprints to the liver". The organ is then able to follow the instructions to produce the clotting protein.
What impact will the treatment have?
NHS England's national medical director Professor Stephen Powis described the therapy as "transformative". Its impact, he said, could be "truly life-changing".
Five years after being part of the clinical trial, Elliott Collins, 34, told the BBC: "I feel cured." Before, "I would have to think about it all the time". Now, "for it to completely disappear", it's changed me "mentally and physically".
The therapy may not prove as effective for all patients, however. Of the 54 men who took part in the clinical trial, two continued to need factor IX injections. "And nobody knows how long it will last." Some research has suggested it could be more than 10 years.
The therapy is also "not considered a true 'cure'", said the BBC, as it won't stop people with the disorder from passing it on genetically.
What's the price tag?
The gene therapy comes at a hefty cost: £2.6 million, making it "one of the world's most expensive" treatments. "England's thrifty drug-cost regulator" (the National Institute for Health and Care Excellence, or Nice) has endorsed the investment for "a limited period" while the drug's efficacy "remains under scrutiny", said Bloomberg.
The financial "deal" between the manufacturer CSL Behring, NHS England and Nice is "bound up in confidentiality agreements", said the BBC, but it is "essentially a performance-related pay for drugs", the "first such deal" that the health service has struck.
Now that its funding has been approved, the therapy will be made available at centres in London, Manchester, Leeds, Bristol, Cambridge, Birmingham and Oxford.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Julia O'Driscoll is the engagement editor. She covers UK and world news, as well as writing lifestyle and travel features. She regularly appears on “The Week Unwrapped” podcast, and hosted The Week's short-form documentary podcast, “The Overview”. Julia was previously the content and social media editor at sustainability consultancy Eco-Age, where she interviewed prominent voices in sustainable fashion and climate movements. She has a master's in liberal arts from Bristol University, and spent a year studying at Charles University in Prague.
-
Can Republicans navigate their narrow House majority?
In the Spotlight This isn't the first time that a party has had no margin for error
By David Faris Published
-
How does Inauguration Day work?
The Explainer Part Constitution, part tradition
By Joel Mathis, The Week US Published
-
When does a Roth 401(k) make more sense?
The Explainer There are several key differences between a Roth 401(k) and a 401(k) that may make one option more beneficial than the other
By Becca Stanek, The Week US Published
-
The UK's first legal drug consumption room
The Explainer 'Potentially transformative moment in UK drugs policy' as The Thistle opens in Glasgow
By The Week UK Published
-
HMPV is spreading in China but there's no need to worry
The Explainer Respiratory illness is common in winter
By Devika Rao, The Week US Published
-
Walking pneumonia cases are picking up pace
The explainer Another respiratory illness to be wary of
By Devika Rao, The Week US Published
-
How can the UK solve the adult social care crisis?
Today's Big Question New commission announced to turn our buckling care sector around: yet more delay or finally a way forward?
By Elizabeth Carr-Ellis, The Week UK Published
-
The future of fluoridated water is up for debate
The Explainer The oral benefits are watery
By Devika Rao, The Week US Published
-
Polycystic ovary syndrome: what it is, how it's treated and why it's often misunderstood
The Explainer PCOS affects millions, but there is still no cure outside of treating symptoms separately
By Theara Coleman, The Week US Published
-
The growing list of conditions weight-loss drugs could help with
The Explainer Ozempic and similar drugs have been linked to possibly helping diseases beyond diabetes and obesity. Are they miracle drugs?
By Theara Coleman, The Week US Published
-
ADHD drugs shortage: what's behind it?
The Explainer Supply chain issues and 'tripling' of prescriptions concerns GPs as problems getting medication become 'desperate'
By The Week UK Published